This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland


Lgr5 Stem Cell Based Organoids and Their Applications in Cancer Research

Hans Clevers, M.D., Ph.D., Group Leader, Hubrecht Institute for Developmental Biology and Stem Cell Research and Professor of
Molecular Genetics, University Medical Center Utrecht and Utrecht University, The Netherlands

Antibody Therapeutic Developments, Pipeline and Progress at Medimmune

Jane Osbourn, Ph.D., Vice President R&D and Site Leader of MedImmune, Cambridge, United Kingdom

Confirmed Sessions and Speakers

Turning Antibody Leads into Drugs

Session Chair:
John McCafferty, Ph.D., Founder and CEO, IONTAS, United Kingdom

Transitioning from Lead Discovery through Pre-clinical/in vivo PoC
Andy Nixon, Ph.D., Vice President, Biotherapeutics Molecule Discovery, Boehringer Ingelheim, USA

Case Study of Antibody Lead to Drug
Francisca Wollerton, Ph.D., Director of Antibody Engineering, F-star Biotechnology, United Kingdom

Immunomodulatory Target Discovery Using Antibody Technologies
Katarina Radosevic, Ph.D., Global Head Biologics Research, Sanofi R&D, France

Anti-CD70 Antibody ARGX-110: Cusatuzumab
Hans de Haard, Ph.D., Chief Scientific Officer, Argenx, Belgium

Applying Antibody Technologies for New Therapeutics
Allan Bradley, Ph.D. Chief Scientific Officer, Kymab, United Kingdom

Addressing Antibody Developability by Mammalian Display

Recent Advances in Immuno-Oncology Approaches

Session Co-Chairs:

John Anderson, Ph.D., Deputy Head of Programme and Professor of Experimental Paediatric Oncology, UCL Great Ormond Street Institute of Child Health, United Kingdom

Paul W.H.I. Parren, Ph.D., Professor, Leiden University Medical Center and EVP, Research & Development, Lava Therapeutics, The Netherlands

Small Molecule Targeting of the CD47 Myeloid Checkpoint
Ton N. Schumacher, Ph.D., Professor of Immunotechnology, Leiden University and Principal Investigator, The Netherlands Cancer Institute, The Netherlands

TEGs - αβT cells Engineered to Express a Defined γδTCR – The Next Generation of CAR T
Jürgen Kuball, M.D., Chief Scientific Officer, Gadeta, The Netherlands

Pablo Umaña, Ph.D., Head of Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Switzerland

Bispecific γδ-T cell Engagers for Cancer Immunotherapy
Hans van der Vliet, M.D., Ph.D., Chief Scientific Officer, Lava Therapeutics, The Netherlands

Chimeric Costimulatory Receptors to Avoid on Target Off Tumour Toxicity
John Anderson, Ph.D., Deputy Head of Programme and Professor of Experimental Paediatric Oncology, UCL Great Ormond Street Institute of Child Health, United Kingdom

Bioinformatics and Repertoires in Antibody Discovery and Development

Session Co-Chairs:

Andrew Martin, D.Phil., Reader in Bioinformatics and Computational Biology, Institute of Structural and Molecular Biology, Division of Biosciences, University College London, United Kingdom

Pierre Bruhns, Ph.D., Director, Unit of Antibodies in Therapy & Pathology and Deputy Director, Department of Immunology, Institut Pasteur, France

Machine Learning and Antibody Developability
Abhinandan Raghavan, Ph.D., Data Scientist, Technology and Functional Lead (Informatics), Novartis, Switzerland

Antibody Repertoires in Response to Haemophilia A, Tools and Problems
Adrian Shepherd, Ph.D., Reader in Computational Biology, Birkbeck College, United Kingdom

30 Years of IMGT: Antibodies from Receptors to Amino Acids, What Have We Learned?
Marie-Paule Lefranc, Ph.D., Founder, IMGT, France

Antigen-specific Repertoires Identification Using Droplet Microfluidics
Pierre Bruhns, Ph.D., Director, Unit of Antibodies in Therapy & Pathology and Deputy Director, Department of Immunology, Institut Pasteur, France

Deep Screening of the B Cell Repertoire to Discover High Quality Antibodies to Challenging Targets
Daniel Lightwood Ph.D., Director, Antibody Discovery, UCB-Celltech, United Kingdom

Confirmed Sessions and Speakers


Antibody Therapeutics for Autoimmune and Neurodegenerative Diseases

Session Chair:
Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer, NovImmune SA, Switzerland

Combination Depleting mAbs for Th1 and Th17 Cells and Tolerance Induction for Autoimmune ‘Cure’
Charles MacKay, Ph.D., Professor, Monash University, Australia

Therapies Targeting Alzheimer’s Disease
Andrea Pfeifer, Ph.D., CEO, AC Immune, Switzerland

Exosome Therapeutics: Delivery of Biologics for the Treatment of CNS Diseases

Tony De Fougerolles, CEO, Evox Therapeutics, United Kingdom

Clinical Developments in Antibody Therapeutics

Session Chair:
Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom

New Antibody Formats and Effector Functions

Session Co-Chairs:

Jeanette L. Jeanette Leusen, Ph.D., Associate Professor, Head Immunotherapy Group and UMAB Facility, Laboratory for Translational Immunology, UMC Utrecht, The Netherlands

Matthias Peipp, Ph.D., Professor and Head of Research, Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University Kiel, Germany

IgG Fc Engineering for FcRn Targeting and Improved Effector Functions
Jan Terje Andersen, Ph.D., Group Leader, Oslo University Hospital, Norway

Novel Formats Including Cross-Mab and 41BB Fusions
Christian Klein, Head Oncology Programs & Department Head Cancer Immunotherapy Discovery, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Switzerland

Dual Targeting Approach Using Bispecific Hemi-Bodies
Gernot Stuhler, Lead, Hemibody Immunotherapy Lab, University Hospital Würzburg, Germany

Fc Receptor Interactions and Tumor Micro-Environment
Mark Cragg, Ph.D., Professor of Experimental Cancer Research, Director
of Cancer Pathway Integrated Postgraduate Programme, University of Southampton, United Kingdom (Invited)

Complement only Fc, Non-glycosylated Engineered IgG
George Georgiou, Ph.D., Professor, Laura Jennings Turner Chair in Engineering, Department of Chemical Engineering, The University of Texas at Austin